Low sensitivity of BinaxNOW RSV in infants by Zuurbier, RP, Bont, LJ, Langedijk, AC, Hamer, M, Korsten, K, Drysdale, SB, Snape, MD, Robinson, H, Pollard, AJ, Martinón-Torres, F, Rodríguez-Tenreiro Sánchez, C, Gómez-Carballa, A, Dacosta-Urbieta, AI, Heikkinen, T, Cunningham, S, van Houten, MA, Wildenbeest, JG

“…<p><strong>Background:</strong><br /> Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can optimize clinical management and minimize use of antibiotics. …”

A genome-wide association study of respiratory syncytial virus infection severity in infants by Johnson, M, Chelysheva, I, Öner, D, McGinley, J, Lin, G-L, O'Connor, D, Robinson, H, Drysdale, SB, Gammin, E, Vernon, S, Muller, J, Wolfenden, H, Westcar, S, Anguvaa, L, Thwaites, RS, Bont, L, Wildenbeest, J, Martinón-Torres, F, Aerssens, J, Openshaw, PJM, Pollard, AJ

“…Respiratory syncytial virus (RSV) is a significant cause of infant morbidity and mortality worldwide; however, understanding the genetic risk factors of severe RSV is incomplete. …”

The impact of infant Bacille Calmette-Guérin vaccination on the immunogenicity of other vaccines: a randomized exploratory study by Maytum, A, Porter, D, de Whalley, P, Thompson, A, Plested, E, Kerridge, S, Liu, X, Smits, G, van der Klis, F, Snape, MD, Clutterbuck, E, Pollard, AJ

“…The effect of the Bacille Calmette-Guérin (BCG) vaccine on the immunogenicity of separately administered serogroup C meningococcal vaccine and other vaccinations was examined in 28 infants randomized to receive BCG at age ≤7 days, at 3 months or after study completion. …”

Clinical and viral factors associated with disease severity and subsequent wheezing in infants with respiratory syncytial virus infection by McGinley, JP, Lin, GL, Öner, D, Golubchik, T, O'Connor, D, Snape, MD, Gruselle, O, Langedijk, AC, Wildenbeest, J, Openshaw, P, Nair, H, Aerssens, J, Bont, L, Martinón-Torres, F, Drysdale, SB, Pollard, AJ

“…Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in infants and young children worldwide. Here we evaluated host demographic and viral factors associated with RSV disease severity in 325 RSV-infected infants under 1 year of age from 3 European countries during 2017–2020. …”

Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine by O'Connor, D, Pinto, MV, Sheerin, D, Tomic, A, Drury, RE, Channon-Wells, S, Galal, U, Dold, C, Robinson, H, Kerridge, S, Plested, E, Hughes, H, Stockdale, L, Sadarangani, M, Snape, MD, Rollier, CS, Levin, M, Pollard, AJ

“…Infants were randomised to receive control immunisations (PCV13 and DTaP‐IPV‐Hib) with or without 4CMenB at 2 and 4 months of age. …”

Simultaneous viral whole-genome sequencing and differential expression profiling in respiratory syncytial virus infection of infants by Lin, G-L, Golubchik, T, Drysdale, S, O'Connor, D, Jefferies, K, Brown, A, de Cesare, M, Bonsall, D, Ansari, MA, Aerssens, J, Bont, L, Openshaw, P, Martinón-Torres, F, Bowden, R, Pollard, AJ

Targeted metagenomics reveals association between severity and pathogen co-detection in infants with respiratory syncytial virus by Lin, G-L, Drysdale, SB, Snape, MD, O'Connor, D, Brown, A, MacIntyre-Cockett, G, Mellado-Gomez, E, de Cesare, M, Ansari, MA, Bonsall, D, Bray, JE, Jolley, KA, Bowden, R, Aerssens, J, Bont, L, Openshaw, PJM, Martinon-Torres, F, Nair, H, Golubchik, T, Pollard, AJ

“…In this study, nasopharyngeal swabs were collected from two cohorts of RSV-positive infants <12 months in Spain, the UK, and the Netherlands during 2017–20. …”

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study by Wildenbeest, JG, Billard, M-N, Zuurbier, RP, Korsten, K, Langedijk, AC, van de Ven, PM, Snape, MD, Pollard, AJ, Drysdale, SB, Pollard, AJ, Robinson, H, Heikkinen, T, Cunningham, S, O'Neill, T, Rizkalla, B, Dacosta-Urbieta, A, Martinón-Torres, F, van Houten, MA, Bont, LJ

“…<p><strong>Background:</strong> Respiratory syncytial virus (RSV) is a major cause of hospitalisation in infants. The burden of RSV infection in healthy term infants has not yet been established. …”

Airway and blood monocyte transcriptomic profiling reveals an antiviral phenotype in infants with severe respiratory syncytial virus infection by Chappin, K, Besteman, SB, Hennus, MP, Wildenbeest, JG, Mokry, M, Bont, LJ, van der Vlist, M, Calis, JJA, Pollard, AJ

The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis by Oguti, B, Ali, A, Andrews, N, Barug, D, Anh Dang, D, Halperin, SA, Thu Hoang, HT, Holder, B, Kampmann, B, Kazi, AM, Langley, JM, Leuridan, E, Madavan, N, Maertens, K, Maldonado, H, Miller, E, Munoz-Rivas, FM, Omer, SB, Pollard, AJ, Rice, TF, Rots, N, Sundaram, ME, Wanlapakorn, N, Voysey, M

“…Blood samples were taken at two timepoints before any DTP-containing vaccines were received by the infant: at birth and at 2-months of age. Decay rates for each antigen were log2-transformed and a mixed effects model was applied. …”

Substantial burden of non-medically attended RSV infection in healthy term infants – an international prospective birth cohort study by Hak, SF, Venekamp, RP, Billard, M-N, van Houten, MA, Pollard, AJ, Heikkinen, T, Cunningham, S, Millar, M, Martinón-Torres, F, Dacosta-Urbieta, A, Bont, LJ, Wildenbeest, JG

“…<p><strong>Background:</strong> During the first year of life, one in four infants develops a symptomatic respiratory syncytial virus (RSV) infection, yet only half seek medical attention. …”

Respiratory Syncytial Virus Consortium in Europe (RESCEU) birth cohort study: defining the burden of infant respiratory syncytial virus disease in Europe by Wildenbeest, JG, Zuurbier, RP, Korsten, K, van Houten, MA, Billard, MN, Derksen-Lazet, N, Snape, MD, Drysdale, SB, Robinson, H, Pollard, AJ, Heikkinen, T, Cunningham, S, Leach, A, Martinón-Torres, F, Rodríguez-Tenreiro Sánchez, C, Gómez-Carballa, A, Bont, LJ, Respiratory Syncytial Virus Consortium in Europe (RESCEU) Investigators

“…<p><strong>Background</strong></p> <p>Respiratory syncytial virus (RSV) causes significant morbidity and mortality in infants worldwide. Although prematurity and cardiopulmonary disease are risk factors for severe disease, the majority of infants hospitalized with RSV are previously healthy. …”

A retrospective cohort study on infant respiratory tract infection hospitalizations and recurrent wheeze and asthma risk: impact of respiratory syncytial virus by van Wijhe, M, Johannesen, CK, Simonsen, L, Jørgensen, IM, Fischer, TK

“…<p><strong>Background:</strong>&nbsp;Infant respiratory syncytial virus infection (RSV) has been associated with asthma later in life. …”

Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants by Zivanovic, N, Öner, D, Abraham, Y, McGinley, J, Drysdale, SB, Wildenbeest, JG, Crabbe, M, Vanhoof, G, Thys, K, Thwaites, RS, Robinson, H, Bont, L, Openshaw, PJM, Martinón-Torres, F, RESCEU Investigators, Pollard, AJ, Aerssens, J

“…This study aimed to investigate biological mechanisms and associated biomarkers underlying RSV disease heterogeneity in young infants, enabling the potential to objectively categorize RSV-infected infants according to their medical needs. …”

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants by Valente Pinto, M, O'Connor, D, Galal, U, Clutterbuck, EA, Robinson, H, Plested, E, Bibi, S, Camara Pellisso, S, Hughes, H, Kerridge, S, Mujadidi, YF, Findlow, H, Borrow, R, Snape, MD, Pollard, AJ

“…We describe the immunogenicity and reactogenicity of the 2 + 1 schedule in infants. <br><strong> Methods<br></strong> Infants were randomized to receive 4CMenB with routine immunizations (test group) at 2, 4, and 12 months or 4CMenB alone at 6, 8, and 13 months of age (control group). …”

Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) — a protocol for two parallel, open-label, randomised controlled trials by Kelly, S, Liu, X, Theiss-Nyland, K, Voysey, M, Murphy, S, Li, G, Nyantaro, M, Gurung, M, Basnet, S, Pokhrel, B, Bijukchhe, SM, Eordogh, A, Gombe, B, Kakande, A, Kerridge, S, Kimbugwe, G, Kusemererwa, S, Lubyayi, L, Luzze, H, Mazur, O, Mujadidi, YF, Nabukenya, S, Nagumo, W-R, Nareeba, T, Noristani, R, O'Reilly, P, Roberts, A, Shah, G, Shrestha, S, Shrestha, LP, Thapa, SB, Kibengo, FM, Sharma, AK, Elliott, A, Shrestha, S, Pollard, AJ

“…New vaccines for other diseases continue to be introduced into the infant immunisation schedule, resulting in an increasingly crowded schedule. …”

Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe by Mao, Z, Li, X, Dacosta-Urbieta, A, Billard, M-N, Wildenbeest, J, Korsten, K, Martinón-Torres, F, Heikkinen, T, Cunningham, S, Snape, MD, Robinson, H, Pollard, AJ, Postma, M, Dervaux, B, Hens, N, Bont, L, Bilcke, J, Beutels, P

“…This study aimed to evaluate the RSV-associated costs and HRQoL effects in infants and their caregivers in four European countries.…”

Group B Streptococcal disease in England (1998 - 2017): a population-based observational study by Kadambari, S, Trotter, CL, Heath, PT, Goldacre, MJ, Pollard, AJ, Goldacre, R

“…<p><strong>Background and Objectives</strong> Group B Streptococcus (GBS) is the leading cause of sepsis and meningitis in infants <90 days. In this study, the burden of GBS disease and mortality in young infants in England was assessed.…”

Viral bronchiolitis management in hospitals in the UK by Carande, EJ, Galiza, EP, Nickless, A, Pollard, AJ, Drysdale, SB

“…<strong>Conclusions</strong> There was wide variation in the management of infants with bronchiolitis in Trusts. Most bronchiolitic infants are not managed optimally in hospitals. …”

Presumed risk factors and biomarkers for severe respiratory syncytial virus disease and related sequelae: Protocol for an observational multicenter, case-control study from the Res... by Jefferies, K, Drysdale, SB, Robinson, H, Clutterbuck, EA, Blackwell, L, McGinley, J, Lin, G-L, Galal, U, Nair, H, Aerssens, J, Öner, D, Langedijk, A, Bont, L, Wildenbeest, JG, Martinon-Torres, F, Rodríguez-Tenreiro Sánchez, C, Nadel, S, Openshaw, P, Thwaites, R, Widjojoatmodjo, M, Zhang, L, Nguyen, TL-A, Giaquinto, C, Giordano, G, Baraldi, E, Pollard, AJ

“…Six hundred thirty infants will be recruited across 3 European countries: the Netherlands, Spain, and the United Kingdom. …”